Welcome to our dedicated page for INTUITIVE SURGICAL SEC filings (Ticker: ISRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Intuitive Surgical filings document operating results, governance matters, capital structure, and material events for a Nasdaq-listed medical technology company focused on robotic-assisted surgery. Its Form 8-K reports furnish quarterly and preliminary financial results, procedure information, and exhibits tied to da Vinci and Ion business performance.
Regulatory filings also cover shareholder voting matters, proxy governance, executive compensation, director elections, and officer-role changes. Other material-event disclosures record completed corporate actions, including the acquisition of da Vinci and Ion distribution operations in Europe, alongside formal disclosures about common stock and financial reporting matters.
Intuitive Surgical VP Corporate Controller Fredrik Widman reported multiple equity transactions on February 26, 2026. He acquired 611 and 378 shares of common stock through the vesting and conversion of previously granted restricted stock units (RSUs), and received a new award of 1,627 RSUs that will vest in 25% annual installments over four years.
To cover statutory tax withholding on the RSU vesting, 303 and 188 shares of common stock were withheld at a price of $506.17 per share, rather than being sold in the open market. After these transactions, his directly held common stock and RSU balances increased, reflecting routine compensation-related activity.
INTUITIVE SURGICAL INC director and CEO David J. Rosa reported multiple equity compensation transactions dated February 26, 2026. He acquired 4,788 performance stock units originally granted on February 28, 2023 and 3,018 performance stock units originally granted on June 12, 2023, after performance criteria were certified as achieved. These performance units are scheduled to vest on February 28, 2026, subject to continued service.
Rosa also received a new grant of 13,441 restricted stock units dated February 26, 2026, which vest 25% per year over four years. In addition, 3,816 and 2,289 previously granted restricted stock units were exercised into common stock on a one-for-one basis, with 1,892 and 1,135 common shares respectively withheld at a price of 506.17 per share to cover statutory tax obligations. After these transactions, he directly owned 232,648 shares of common stock.
Intuitive Surgical director Gary S. Guthart reported multiple equity award transactions. He received 8,778 performance stock units granted on February 28, 2023 after performance criteria were achieved, which are scheduled to vest on February 28, 2026, subject to continued service.
He also acquired 4,960 and 3,433 shares of common stock through the vesting and conversion of restricted stock units, with related dispositions of 2,460 and 1,703 shares at $506.17 per share to cover statutory tax withholding obligations. Following these transactions, he holds 9,251 shares of common stock directly, plus additional indirect holdings through family trusts.
Intuitive Surgical senior vice president Mark Brosius reported several equity compensation transactions. He received 2,793 performance stock units originally granted on February 28, 2023, after the company confirmed the required performance goals were achieved. These PSUs are scheduled to vest on February 28, 2026, subject to continued service.
He also received a new grant of 4,928 restricted stock units dated February 26, 2026, which vest 25% annually over four years. Previously granted RSUs from 2024 and 2025 partially vested, converting into 1,622 and 973 shares of common stock, with 805 and 483 shares respectively withheld at a price of $506.17 per share to cover statutory tax obligations.
Intuitive Surgical (ISRG) executive Myriam Curet reported option exercises, RSU vesting, and related share sales through a trust. On February 10, 2026, a trust associated with Curet acquired 838 common shares from vested RSUs and 105 shares via stock option exercise, and disposed of 417 shares to cover taxes. The trust also sold 105 shares at $494.65 on February 10 and 421 shares at $494.96 on February 11 in open-market transactions under a Rule 10b5-1 trading plan. Following these transactions, the trust held 409 common shares, while Curet directly held derivative positions including 1,257 stock options and 838 RSUs subject to the disclosed vesting schedules.
Intuitive Surgical officer Fredrik Widman, VP Corporate Controller, reported several equity transactions around restricted stock unit (RSU) vesting. On February 10, 2026, 567 RSUs converted into an equal number of common shares at an exercise price of $0.0, increasing his directly held common stock to 1,095 shares.
Also on February 10, 302 common shares were disposed of at $492.84 per share to cover statutory tax withholding, leaving 793 common shares directly owned. After these transactions, Widman held 567 RSUs directly.
On February 11, 2026, Widman executed an open‑market sale of 133 common shares at $494.96 per share under a pre‑established Rule 10b5‑1 trading plan that expires on May 21, 2026, resulting in 660 common shares directly owned.
An ISRG shareholder plans to sell 133 common shares under Rule 144 through Morgan Stanley Smith Barney LLC Executive Financial Services. The planned sale has an aggregate market value of 65829.68 and is expected around 02/11/2026 on the NASDAQ exchange.
The shares were acquired as restricted stock from the issuer on 02/10/2026, with payment also dated 02/10/2026. The issuer has 355130237 shares outstanding, providing context for the relative size of this proposed sale.
Curet McAdams filed a notice of proposed sale under Rule 144 to sell 421 shares of the issuer’s common stock, with an aggregate market value of $208,378.16, through Morgan Stanley Smith Barney LLC on or around 02/11/2026 on NASDAQ.
The 421 common shares were acquired from the issuer on 02/10/2026 as restricted stock, with the same date shown as the payment date and the consideration marked as not applicable. In the prior three months, McAdams also completed several smaller common stock sales with disclosed gross proceeds.
Intuitive Surgical CEO David J. Rosa reported routine stock-based compensation activity. On February 10, 2026, 1,436 restricted stock units from a February 10, 2023 grant vested and converted into the same number of common shares at an exercise price of $0.0.
A portion of these shares, 724 common shares at $492.84 per share, was withheld to cover statutory tax obligations. After these transactions, Rosa directly holds 229,570 shares of Intuitive Surgical common stock. The RSUs vest in four equal annual installments of 25%, contingent on continued service.